Goldman Sachs’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-184,000
| Closed | -$753K | – | 6232 |
|
|
2018
Q1 | $753K | Buy |
184,000
+173,000
| +1,573% | +$806K | ﹤0.01% | 4233 |
|
|
2017
Q4 | $51K | Sell |
11,000
-3,300
| -23% | -$18.2K | ﹤0.01% | 5934 |
|
|
2017
Q3 | $102K | Sell |
14,300
-200
| -1% | -$1.44K | ﹤0.01% | 6053 |
|
|
2017
Q2 | $105K | Sell |
14,500
-6,000
| -29% | -$37.5K | ﹤0.01% | 6107 |
|
|
2017
Q1 | $126K | Sell |
20,500
-11,900
| -37% | -$65.2K | ﹤0.01% | 5961 |
|
|
2016
Q4 | $190K | Buy |
32,400
+23,800
| +277% | +$130K | ﹤0.01% | 5800 |
|
|
2016
Q3 | $46K | Sell |
8,600
-80,100
| -90% | -$432K | ﹤0.01% | 6504 |
|
|
2016
Q2 | $587K | Sell |
88,700
-112,900
| -56% | -$631K | ﹤0.01% | 4705 |
|
|
2016
Q1 | $941K | Buy |
201,600
+192,400
| +2,091% | +$768K | ﹤0.01% | 4121 |
|
|
2015
Q4 | $46K | Sell |
9,200
-5,200
| -36% | -$24.7K | ﹤0.01% | 6581 |
|
|
2015
Q3 | $51K | Sell |
14,400
-25,600
| -64% | -$171K | ﹤0.01% | 6784 |
|
|
2015
Q2 | $399K | Buy |
40,000
+34,700
| +655% | +$372K | ﹤0.01% | 5435 |
|
|
2015
Q1 | $67K | Sell |
5,300
-71,200
| -93% | -$915K | ﹤0.01% | 6597 |
|
|
2014
Q4 | $1.08M | Sell |
76,500
-62,000
| -45% | -$961K | ﹤0.01% | 4479 |
|
|
2014
Q3 | $1.9M | Buy |
138,500
+115,200
| +494% | +$1.76M | ﹤0.01% | 3982 |
|
|
2014
Q2 | $358K | Sell |
23,300
-130,600
| -85% | -$1.85M | ﹤0.01% | 5630 |
|
|
2014
Q1 | $2.62M | Buy |
153,900
+13,000
| +9% | +$196K | ﹤0.01% | 3714 |
|
|
2013
Q4 | $1.82M | Buy |
+140,900
| New | +$1.68M | ﹤0.01% | 4166 |
|
|
2013
Q3 | – | Sell |
-1,129,800
| Closed | -$8.44M | – | 6782 |
|
|
2013
Q2 | $8.44M | Buy |
+1,129,800
| New | +$8.83M | ﹤0.01% | 2230 |
|
Goldman Sachs's KERX Position: Q4 2018 in Review
Goldman Sachs sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 70,113 shares — an estimated $238K sold.
Goldman Sachs first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $7.74M in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Goldman Sachs reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Goldman Sachs sold 70,113 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $238K.
- Goldman Sachs first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Goldman Sachs's Keryx Biopharmaceuticals Inc position peaked at $7.74M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.